The XI Symposium "Pharmacoeconomics in Oncology" was held within the VI St. Petersburg International Oncology Forum “White Nights 2020” on June 25th, 2020
The XI Symposium "Pharmacoeconomics in Oncology" was held within the VI St. Petersburg International Oncology Forum “White Nights 2020” on June 25th, 2020.
Andrey Pavlysh, North-western State Medical University named after I.I.Mechnikov; FSBI «N.N. Petrov NMRC of oncology» of the Ministry of Healthcare of the Russian Federation
Aleksey Kolbin, Pavlov First St.Petersburg State Medical University
The presentations were given by:
Liberman Ana, Dr. rer. nat., Research Associate with Supervisory Responsibilities, Institute for Quality and Efficiency in Health Care (IQWiG), Cologne (Germany). Dr. Liberman gave a talk on the Early benefit assessment of drugs;
Rupprecht Christoph J., Head of the Department Health Policy /Health Economics AOK Rheinland/Hamburg – Die Gesundheitskasse, Düsseldorf (Germany) with the title: Strengths but also weaknesses of the German regulatory system to ensure quality, efficiency and responsible pricing of innovative pharmaceuticals;
Aleksey Kolbin, Pavlov First St.Petersburg State Medical University, St. Petersburg - “Real World Data. From a glossary to oncology practice”;
Aleksey Kurylev, Pavlov First St.Petersburg State Medical University; FSBI «N.N. Petrov NMRC of oncology» of the Ministry of Healthcare of the Russian Federation - “Real World Data in practice cancer care”;
Olga Shevchenko, Pavlov First St.Petersburg State Medical University - “Pragmatic clinical trials”;
Sergey Zyryanov, RUDN University, Moscow - “Financial burden of modern pharmacotherapy in oncology: can the costs be reduced?”;
Olga Zelenova, Federal Research Institute for Health Organization and Informatics of Ministry of Health of the Russian Federation, Moscow – “Clinical and economic approaches to the development of new clinical statistical groups for nutritional support of cancer patients after chemotherapy”;
Andrey Pavlysh, North-Western State Medical University named after I.I. Mechnikov; FSBI «N.N. Petrov NMRC of oncology» of the Ministry of Healthcare of the Russian Federation – “Hospital-based HTA in Russia: principles of organization and performance”;
Alla Rudakova, FSBI St-Petersburg State Chemical Pharmaceutical University of the Ministry of Healthcare of Russia – “Pharmacoeconomic aspects of cancer patients vaccination to prevent pneumococcal infection”;
Georgy Khachatryan, Center for Healthcare Quality Assessment and Control of the Ministry of Health of the Russian Federation, Moscow – “Prospects for Healthcare technologies assessment and pricing in oncology in the Russian Federation”.
The Final Resolution adopted by the XI Symposium “Pharmacoeconomics in Oncology”:
1. Early assessment of drugs in oncology is a modern highly effective method of various oncological diseases and hematologic malignancies management. Early assessment of health care technologies enables fast response to changes in anti-tumor drugs market in Germany.
2. The submitted data on the specifics of financing the German healthcare system allows for the conclusion about the benefits and challenges in using HTA data by insurance companies that form the basis of the medicine budget of health care organizations in the North Rhein-Westfalen region.
3. One of the leading trends in modern healthcare technology assessment is the study of RWD (real world data) - "real world" or "real clinical practice" data and RWE (real world evidence). Research in this field is in dire need of consensus on terminology and methodology between different groups of scientists. Thus, a training manual has been prepared by a group of authors and will be published in the near future.
4. Continuing on the topic of the RWD/RWE the questions of practical use of real clinical practice data for clinical and economic analysis in cancer care, possibility of data aggregation from different sources and prospects of work in this direction were considered.
5. Considering cancer clinical trials prospects allows us to conclude that high use of pragmatic studies is reasonable in view of the shorter time required to conduct them, greater flexibility in obtaining informed consent and less stringent requirements for patient selection criteria.
6. Currently some tools to reduce financial burden of modern pharmacotherapy in oncology has been developed and tested in Russia. Herewith both for the treatment of prior disease with the help of specific therapy, and in nutritional support.
7. Hospital-based HTA is still one of the most promising tools for supporting the resource provision of health care institutions at the local level, requiring outreach with decision makers in the health care system.
8. Vaccination of cancer patients to prevent pneumococcal infection is a proven effective method in managing complications of a number of malignant tumors.
9. Health technology assessment system in the Russian Federation is formed, submitted documents, including pharmacoeconomic studies, are being regularly assessed and development of HTA system in the Russian Federation goes on based on international approaches.